PBYI

$0.00

(

+0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Puma Biotechnology Inc

NASDAQ | PBYI

5.29

USD

+$0.00

(

+0.00%

)

At Close (As of Oct 13, 2025)

$257.90M

Market Cap

5.17

P/E Ratio

0.99

EPS

$6.07

52 Week High

$2.31

52 Week Low

HEALTHCARE

Sector

PBYI Chart

Recent Chart
Price Action

PBYI Technicals

Tags:

PBYI Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $166M
Total Revenue $230M
Cost Of Revenue $64M
Costof Goods And Services Sold $64M
Operating Income $31M
Selling General And Administrative $81M
Research And Development $55M
Operating Expenses $135M
Investment Income Net -
Net Interest Income -$7.7M
Interest Income $4.7M
Interest Expense $12M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $12M
Income Before Tax $24M
Income Tax Expense -$6.2M
Interest And Debt Expense -
Net Income From Continuing Operations $30M
Comprehensive Income Net Of Tax -
Ebit $37M
Ebitda $48M
Net Income $30M

Revenue & Profitability

Earnings Performance

PBYI Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $213M
Total Current Assets $148M
Cash And Cash Equivalents At Carrying Value $69M
Cash And Short Term Investments $69M
Inventory $8.7M
Current Net Receivables $32M
Total Non Current Assets $66M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets $51M
Intangible Assets Excluding Goodwill $51M
Goodwill -
Investments -
Long Term Investments -
Short Term Investments $32M
Other Current Assets $6M
Other Non Current Assets -
Total Liabilities $121M
Total Current Liabilities $96M
Current Accounts Payable $5.5M
Deferred Revenue -
Current Debt -
Short Term Debt $56M
Total Non Current Liabilities $25M
Capital Lease Obligations $7M
Long Term Debt $22M
Current Long Term Debt $45M
Long Term Debt Noncurrent -
Short Long Term Debt Total $74M
Other Current Liabilities $34M
Other Non Current Liabilities $1.8M
Total Shareholder Equity $92M
Treasury Stock -
Retained Earnings -$1.3B
Common Stock $5K
Common Stock Shares Outstanding $49M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow $39M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $12M
Capital Expenditures $56K
Change In Receivables -
Change In Inventory -$1.6M
Profit Loss -
Cashflow From Investment -$20M
Cashflow From Financing -$34M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income $30M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $166M
Total Revenue $230M
Cost Of Revenue $64M
Costof Goods And Services Sold $64M
Operating Income $31M
Selling General And Administrative $81M
Research And Development $55M
Operating Expenses $135M
Investment Income Net -
Net Interest Income -$7.7M
Interest Income $4.7M
Interest Expense $12M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $12M
Income Before Tax $24M
Income Tax Expense -$6.2M
Interest And Debt Expense -
Net Income From Continuing Operations $30M
Comprehensive Income Net Of Tax -
Ebit $37M
Ebitda $48M
Net Income $30M

PBYI News

PBYI Profile

Puma Biotechnology Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative therapies to enhance cancer treatment outcomes globally. Headquartered in Los Angeles, California, the company leverages advanced therapeutics and a robust pipeline, primarily focusing on precision medicine to target specific cancer types. With a commitment to addressing unmet medical needs in oncology, Puma is poised to play a significant role in the evolving landscape of cancer care through its proprietary drug candidates.

VHAI
-25.00%
$0.00
YYAI
-12.69%
$0.16
STAI
+39.44%
$0.62
CGBS
-39.47%
$0.03
BURU
+6.25%
$0.50
PLUG
+13.30%
$3.87
ELBM
+334.95%
$7.17
GWH
+118.14%
$9.07
BITF
+28.33%
$5.39
RGTI
+20.26%
$52.82
NVDA
+2.98%
$188.62
ASST
-35.33%
$1.00
BYND
-48.50%
$1.03
IONZ
-35.04%
$2.21
NVTS
+23.51%
$10.16
JOBY
+2.94%
$16.76
ETHD
+16.10%
$3.82
DNN
+6.94%
$3.07
CAN
+33.93%
$1.45
SNAP
-7.15%
$7.78
QBTS
+23.97%
$40.93
INTC
+2.03%
$37.11
GPUS
-12.50%
$0.41
WULF
-0.58%
$13.51
F
+1.27%
$11.55
AXDX
-61.36%
$0.03
BBD
+1.30%
$3.10
CLF
+4.66%
$13.79
TSLA
+5.01%
$434.23
QS
+16.36%
$17.10
CRML
+56.07%
$23.38
NIO
+6.59%
$7.15
RR
-9.34%
$5.92
TLRY
-1.74%
$1.69
ACHR
+6.09%
$12.70
AMD
+0.40%
$215.76
PWM
+12.50%
$1.17
NAK
+29.80%
$2.63
SOUN
+10.25%
$19.14
RXRX
+4.41%
$5.55
ONDS
+17.24%
$10.81
CIFR
+19.77%
$20.32
MP
+21.94%
$95.52
LAES
+13.49%
$6.14
APLD
+2.14%
$34.71
BTBT
+5.58%
$3.97
VALE
-2.53%
$10.75
SOFI
+4.45%
$27.35
DVLT
-12.36%
$1.66
USAR
+17.01%
$38.15
IREN
+7.31%
$64.14
DFLI
+41.35%
$1.54
PFE
-0.30%
$24.70
WBD
-3.22%
$17.10
QUBT
+12.85%
$21.46
ABAT
+33.25%
$8.99
UAMY
+35.91%
$16.59
RMBL
+60.50%
$3.21
EOSE
+23.62%
$17.08
EPWK
-8.00%
$0.08
ADD
-25.47%
$0.05
ADAP
-0.64%
$0.18
CORZ
+2.66%
$18.52
XCH
+103.41%
$1.68
UUUU
+18.40%
$24.08
AAL
+1.51%
$11.69
RIG
+3.24%
$3.18
MARA
+9.43%
$20.40
TMQ
-9.46%
$5.93
NAKA
-4.05%
$0.83
PLTR
+0.84%
$176.92
SRM
+53.27%
$10.30
NOK
-1.79%
$5.22
IONQ
+18.72%
$83.88
RF
+1.75%
$24.58
BMNR
+7.40%
$56.35
GDXD
-12.99%
$0.74
T
-1.06%
$25.59
QSI
+26.28%
$2.10
BULL
+1.62%
$11.58
NB
+3.81%
$10.78
CLSK
+2.49%
$19.76
BINI
-55.00%
$0.63
MULN
-55.00%
$0.63
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
AMZN
+1.81%
$220.30
AVGO
-5.90%
$324.63
NEHC
-8.12%
$2.60
WLGS
-5.57%
$0.04
BTG
+3.87%
$5.27
WWR
0.00%
$1.98
KDLY
-7.21%
$0.87
AMC
+0.68%
$2.95
ETWO
0.00%
$3.30
AAPL
+1.24%
$248.32
OKLO
+16.20%
$171.00
HOOD
+1.03%
$140.40
PMAX
+44.78%
$3.75
HPE
+2.76%
$25.07
VHAI
-25.00%
$0.00
YYAI
-12.69%
$0.16
STAI
+39.44%
$0.62
CGBS
-39.47%
$0.03
BURU
+6.25%
$0.50
PLUG
+13.30%
$3.87
ELBM
+334.95%
$7.17
GWH
+118.14%
$9.07
BITF
+28.33%
$5.39
RGTI
+20.26%
$52.82
NVDA
+2.98%
$188.62
ASST
-35.33%
$1.00
BYND
-48.50%
$1.03
IONZ
-35.04%
$2.21
NVTS
+23.51%
$10.16
JOBY
+2.94%
$16.76
ETHD
+16.10%
$3.82
DNN
+6.94%
$3.07
CAN
+33.93%
$1.45
SNAP
-7.15%
$7.78
QBTS
+23.97%
$40.93
INTC
+2.03%
$37.11
GPUS
-12.50%
$0.41
WULF
-0.58%
$13.51
F
+1.27%
$11.55
AXDX
-61.36%
$0.03
BBD
+1.30%
$3.10
CLF
+4.66%
$13.79
TSLA
+5.01%
$434.23
QS
+16.36%
$17.10
CRML
+56.07%
$23.38
NIO
+6.59%
$7.15
RR
-9.34%
$5.92
TLRY
-1.74%
$1.69
ACHR
+6.09%
$12.70
AMD
+0.40%
$215.76
PWM
+12.50%
$1.17
NAK
+29.80%
$2.63
SOUN
+10.25%
$19.14
RXRX
+4.41%
$5.55
ONDS
+17.24%
$10.81
CIFR
+19.77%
$20.32
MP
+21.94%
$95.52
LAES
+13.49%
$6.14
APLD
+2.14%
$34.71
BTBT
+5.58%
$3.97
VALE
-2.53%
$10.75
SOFI
+4.45%
$27.35
DVLT
-12.36%
$1.66
USAR
+17.01%
$38.15
IREN
+7.31%
$64.14
DFLI
+41.35%
$1.54
PFE
-0.30%
$24.70
WBD
-3.22%
$17.10
QUBT
+12.85%
$21.46
ABAT
+33.25%
$8.99
UAMY
+35.91%
$16.59
RMBL
+60.50%
$3.21
EOSE
+23.62%
$17.08
EPWK
-8.00%
$0.08
ADD
-25.47%
$0.05
ADAP
-0.64%
$0.18
CORZ
+2.66%
$18.52
XCH
+103.41%
$1.68
UUUU
+18.40%
$24.08
AAL
+1.51%
$11.69
RIG
+3.24%
$3.18
MARA
+9.43%
$20.40
TMQ
-9.46%
$5.93
NAKA
-4.05%
$0.83
PLTR
+0.84%
$176.92
SRM
+53.27%
$10.30
NOK
-1.79%
$5.22
IONQ
+18.72%
$83.88
RF
+1.75%
$24.58
BMNR
+7.40%
$56.35
GDXD
-12.99%
$0.74
T
-1.06%
$25.59
QSI
+26.28%
$2.10
BULL
+1.62%
$11.58
NB
+3.81%
$10.78
CLSK
+2.49%
$19.76
BINI
-55.00%
$0.63
MULN
-55.00%
$0.63
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
AMZN
+1.81%
$220.30
AVGO
-5.90%
$324.63
NEHC
-8.12%
$2.60
WLGS
-5.57%
$0.04
BTG
+3.87%
$5.27
WWR
0.00%
$1.98
KDLY
-7.21%
$0.87
AMC
+0.68%
$2.95
ETWO
0.00%
$3.30
AAPL
+1.24%
$248.32
OKLO
+16.20%
$171.00
HOOD
+1.03%
$140.40
PMAX
+44.78%
$3.75
HPE
+2.76%
$25.07
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.